Dr. Mitton-Fry’s research team is dedicated to inventing cures for multidrug-resistant bacterial infections. The lab focuses primarily on the discovery of Novel Bacterial Topoisomerase Inhibitors (NBTIs), compounds which can overcome resistance by means of their differentiated binding mode. The group is also undertaking anticancer research in collaboration with Professor Nicholas Denko. Dr. Mitton-Fry also collaborates with with Prof. Daniel Wozniak on bacteriophage therapy. The lab uses the tools of synthetic medicinal chemistry to design and prepare innovative new molecules, and we collaborate broadly to evaluate their biological, pharmaceutical, and toxicological properties.